Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, et al. "Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models." PLoS ONE. 2012;7(1):e30815.